期刊文献+

沙格列汀联用门冬胰岛素30治疗2型糖尿病的疗效观察 被引量:4

下载PDF
导出
摘要 目的探讨2型糖尿病患者采用沙格列汀联用门冬胰岛素30治疗的临床疗效。方法 86例使用诺和锐30笔芯(>50 U/d)及联用二甲双胍、拜糖苹等口服药物治疗,空腹及餐后血糖仍控制不佳的2型糖尿病患者,加用沙格列汀治疗1周,观察患者血糖的变化。结果应用沙格列汀联用胰岛素治疗第3天时,患者早餐前、早餐后、中餐前、晚餐前及睡前指血糖分别为分别为(11.24±2.50)、(15.30±4.45)、(13.53±2.93)、(14.28±2.94)、(11.64±2.50)mmol/L,与治疗前相比差异具有统计学意义(P<0.05);治疗第6天后,各时间点血糖较第3天有进一步的下降,与治疗前相比差异具有统计学意义(P<0.05);患者胰岛素的日总用量与治疗前比较明显减少(P<0.05)。结论沙格列汀联用门冬胰岛素30治疗2型糖尿病可使血糖下降的同时,胰岛素日总用量也减少,且无一例低血糖发作。
出处 《中国现代药物应用》 2016年第16期139-140,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献4

二级参考文献32

  • 1杜玉茗,宋利华,尚涛,杜建鹏.老年2型糖尿病患者胰岛素加用二肽基肽酶Ⅳ抑制剂治疗的安全性及疗效[J].中国老年学杂志,2014,34(10):2688-2689. 被引量:6
  • 2杨毅华,许琪,张伟斌,等.门冬胰岛素30对初诊2型糖尿病胰岛B细胞功能的影响及疗效观察[J].中国实用内科杂志,2008,28(4):294,316.
  • 3Sanke H, Mita T, Yoshii H, et al. Relationship between olfactory dys- function and cognitive impairment in elderly patients with type 2 diabe- tes mellitus [ J ]. Diabetes Res Clin Pract,2014,106 ( 3 ) :465 -473.
  • 4Cano Megias M, Guisado Vasco P. Type 2 diabetes mellitus in elderly institutionalized patients[ J]. Rev Clin Esp ,2014,214(9 ) :521 - 528.
  • 5Sun Y, Shao L, Niu X, et al. Clinical effectiveness of Novolin? 30R versus Lantus? combined with Glucobay? treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglyeaemic agents: A randomized study [ J ]. J lnt Med Res,2014,42 (4) :993 - 1001.
  • 6Karagiannis T,Boura P';Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors : a perspective "review[J]. Ther Adv Drug Saf, 2014,5 (3) : 138-146.
  • 7Davidson JA. Tolerability of'saxagliptin in patients with inadequat- ely controlled type 2 diabetes:results from 6 phase HI studies[J]. Manag Care Pharm,2014,20(2): 120-129.
  • 8Li CJ,Liu XJ,Bai L,et al. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemie agents [J]. Diabetal Metab Syndr, 2014,31 (6) :69.
  • 9Messori A,Fadda V,Maratea D,et al. Testing "the therapeutic equivalence of alogliptin,linagliptin,saxagliptin,sitagliptin or viIdagliptin as monotherapy or in combination with mefformin in patients with type 2 diabetes. Diabetes Ther,2014,5(1):341-344.
  • 10Baetta R,Corsini A. Pharmacology of dipeptidyl diptidase-4 inhibitors : similarities and differences [J]. Drugs, 2011,30 : 71 (11) : 1441-1467.

共引文献20

同被引文献25

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部